

Product Data Sheet

Product Name: HPG1860

Cat. No.: GC92033

Chemical Properties

Cas. No. 2226133-29-3

Chemical Name 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methyl]-2-methyl-1-piperazinyl]-4-methoxy-6-benzothiazolecarboxylic acid

SMILES COC1=C2C(SC(N3CCN(CC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)C[C@H]3C)=N2)=CC(C(O)=O)=C1


Formula $C_{27}H_{26}Cl_2N_4O_4S$ M.Wt 573.5

Solubility DMSO: Sparingly soluble: 1-10 mg/ml, Ethanol: Sparingly soluble: 1-10 mg/ml Storage $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

HPG1860 is a farnesoid X receptor (FXR) agonist.¹ It induces luminescence in a reporter assay using HEK293T cells expressing human FXR ($EC_{50} = 18$ nM). *In vivo*, HPG1860 (1, 3, or 10 mg/kg per day) decreases the serum levels of alanine transaminase (ALT) and total cholesterol, as well as hepatic inflammation, fat levels, and fibrosis, in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat diet and carbon tetrachloride (CCl_4).

References:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[1]. Mo, C., Xu, X., Zhang, P., et al. Discovery of HPG1860, a structurally novel nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitis. *J. Med. Chem.* 66(14)9363-9375(2023).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA